|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heintz AP, Odicino F, Maisonneuve P,
Beller U, Benedet JL, Creasman WT, Ngan HY and Pecorelli S:
Carcinoma of the ovary. Int J Gynaecol Obstet. 83(Suppl 1):
135–166. 2003. View Article : Google Scholar
|
|
3
|
Jelovac D and Armstrong DK: Recent
progress in the diagnosis and treatment of ovarian cancer. CA
Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Isolation of a novel gene underlying
Batten disease, CLN3. The International Batten Disease Consortium.
Cell. 82:949–957. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rakheja D, Narayan SB, Pastor JV and
Bennett MJ: CLN3P, the Batten disease protein, localizes to
membrane lipid rafts (detergent-resistant membranes). Biochem
Biophys Res Commun. 317:988–991. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Phillips SN, Benedict JW, Weimer JM and
Pearce DA: CLN3, the protein associated with batten disease:
Structure, function and localization. J Neurosci Res. 79:573–583.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Metcalf DJ, Calvi AA, Seaman M, Mitchison
HM and Cutler DF: Loss of the Batten disease gene CLN3 prevents
exit from the TGN of the mannose 6-phosphate receptor. Traffic.
9:1905–1914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cortese A, Tucci A, Piccolo G, Galimberti
CA, Fratta P, Marchioni E, Grampa G, Cereda C, Grieco G, Ricca I,
et al: Novel CLN3 mutation causing autophagic vacuolar myopathy.
Neurology. 82:2072–2076. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Puranam KL, Guo WX, Qian WH, Nikbakht K
and Boustany RM: CLN3 defines a novel antiapoptotic pathway
operative in neurodegeneration and mediated by ceramide. Mol Genet
Metab. 66:294–308. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Narayan SB, Rakheja D, Pastor JV,
Rosenblatt K, Greene SR, Yang J, Wolf BA and Bennett MJ:
Over-expression of CLN3P, the Batten disease protein, inhibits
PANDER-induced apoptosis in neuroblastoma cells: Further evidence
that CLN3P has anti-apoptotic properties. Mol Genet Metab.
88:178–183. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rylova SN, Amalfitano A, Persaud-Sawin DA,
Guo WX, Chang J, Jansen PJ, Proia AD and Boustany RM: The CLN3 gene
is a novel molecular target for cancer drug discovery. Cancer Res.
62:801–808. 2002.PubMed/NCBI
|
|
12
|
Zhu X, Huang Z, Chen Y, Zhou J, Hu S, Zhi
Q, Song S, Wang Y, Wan D, Gu W, et al: Effect of CLN3 silencing by
RNA interference on the proliferation and apoptosis of human
colorectal cancer cells. Biomed Pharmacother. 68:253–258. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu D, Liu J, Wu B, Tu B, Zhu W and Luo J:
The Batten disease gene CLN3 confers resistance to endoplasmic
reticulum stress induced by tunicamycin. Biochem Biophys Res
Commun. 447:115–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dean M, Rzhetsky A and Allikmets R: The
human ATP-binding cassette (ABC) transporter superfamily. Genome
Res. 11:1156–1166. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Izquierdo MA, Neefjes JJ, Mathari AE,
Flens MJ, Scheffer GL and Scheper RJ: Overexpression of the ABC
transporter TAP in multidrug-resistant human cancer cell lines. Br
J Cancer. 74:1961–1967. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nooter K and Stoter G: Molecular
mechanisms of multidrug resistance in cancer chemotherapy. Pathol
Res Pract. 192:768–780. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Breier A, Gibalova L, Seres M, Barancik M
and Sulova Z: New insight into p-glycoprotein as a drug target.
Anticancer Agents Med Chem. 13:159–170. 2013. View Article : Google Scholar
|
|
18
|
Baguley BC: Multiple drug resistance
mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE
and Gottesman MM: P-glycoprotein: From genomics to mechanism.
Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sauna ZE, Kim IW and Ambudkar SV: Genomics
and the mechanism of P-glycoprotein (ABCB1). J Bioenerg Biomembr.
39:481–487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Glavinas H, Krajcsi P, Cserepes J and
Sarkadi B: The role of ABC transporters in drug resistance,
metabolism and toxicity. Curr Drug Deliv. 1:27–42. 2004. View Article : Google Scholar
|
|
22
|
Tecedor L, Stein CS, Schultz ML, Farwanah
H, Sandhoff K and Davidson BL: CLN3 loss disturbs membrane
microdomain properties and protein transport in brain endothelial
cells. J Neurosci. 33:18065–18079. 2013. View Article : Google Scholar : PubMed/NCBI
|
